Exploration of Vaccine Candidates against Avian
Pathogenic E. coli Using Proteome Mining
Amara Saif1, Ayesha Siddiqa1,
Muhammad Imran2, Moazur Rahman3,
Muhammad Muddassar4,
Sakandar Rauf5,
Nayla Munawar6* and Muhammad Saleem1*
1School
of Biological Sciences, University of the Punjab,
Lahore; 2KAM School of Life Sciences,
Forman Christian College (A Chartered
University), University
Lahore; 3Centre of Excellence in
Molecular Biology, University of the Punjab, Lahore;
4Department
of Biosciences, COMSATS University, Islamabad; 5School
of Biochemistry and Biotechnology, University of
the Punjab, Lahore; 6Department of Chemistry,
College of Science, United Arab Emirates University, Al
Ain, 15551, UAE.
Avian Pathogenic
Escherichia coli (APEC) is a major causative agent
of avian colibacillosis, causing significant financial
losses to the poultry industry. Current vaccines offer
limited protection and also pose logistical challenges
related to storage and administration. Considering this
fact, a subtractive proteome analysis along with a
reverse vaccinology approach was performed for the
screening of promising vaccine candidates that would
offer broad protection against heterologous serotypes of
APEC. O1, O2, and O78 are APEC's most prevalent and
pathogenic serotypes, responsible for over 80% of
infections in poultry. Therefore, the essential, highly
virulent, and strongly antigenic outer membrane proteins
(OMPs) shared among these pathogenic serotypes of APEC
were screened through comprehensive
In Silico
analysis. Thus, six OMPs were identified as viable
vaccine targets, including OmpA, PapC, Wza, YehB,
PhoE, and
EtsC. These OMPs belong to the four
functional families: outer membrane protectin,
transporters, capsular biogenesis, and fimbrial
biogenesis. Afterwards, a novel chimeric vaccine was
designed against APEC by using four B-cell, four CTL,
and five HTL epitopes, which were highly conserved among
the three highly pathogenic serotypes. Molecular docking
and dynamic simulations revealed the stable and
high-affinity interactions between the constructed
chimeric vaccine and the mammalian TLR4 receptor.
Nonetheless, in vitro and in vivo
experimental validation will be required to confirm the
immunogenicity and protective efficacy of the vaccine
ensemble.
To Cite This Article:
Saif A, Siddiqa A, Imran M, Rahman M, Muddassar M,
Rauf S, Munawar N and
Saleem M, 2026. Exploration of vaccine candidates
against avian pathogenic E. coli using proteome
mining. Pak Vet J, 2026, 46(10): 2407-2419.
http://dx.doi.org/10.29261/pakvetj/2026.241